Commerce Dashboard

Sun Pharmaceuticals

Go Back

Sun Pharmaceuticals

  • World’s fifth largest specialty generic pharmaceutical company
  • Serves over 150 markets across the world
  • More than 2,000 marketed products
  • More than 40 manufacturing sites
  • In FY20, company’s total income reached Rs 33,473.48 crore (US$ 4.75 billion)

Sun Pharmaceuticals is the largest pharmaceutical company from India and the fifth largest specialty generic company in the world. It has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets and capsules. Its businesses include producing generics, branded generics, speciality, over the counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates in the full range of dosage forms. It also produces specialty APIs. In FY19, US formulations contributed the most to company’s sales with 37 per cent, followed by India branded formulations at 26 per cent.

Company Website:

Sun Pharma – Reaching People. Touching Lives.

2019 Sun Pharma and AstraZeneca enter into License agreement for novel oncology products in China
Sun pharma arm Sun Pharmaceuticals Industries acquires its remaining 3.04 per cent stake in PJSC Biosintez, Russia.
Sun Pharma and China Medical System Holdings entered into licensing agreement for generic products in Mainland China
2018 Sun Pharma to acquire Pola Pharma in Japan
2018 Sales of Rs 27,956 crore (US$ 4 billion) in FY18; Announced acquisition of US-based speciality pharmaceutical company Avenue Therapeutics for Rs 1502.635 crore (US$ 215 million)
2017 Agreement signed with National Institute of Virology, India to fight Zika, Chikungunya and Dengue
2013 Became world’s fifth largest specialty generic pharmaceutical company with acquisition of Ranbaxy
2000 Acquired Pradeep Drug Company
1997 First international acquisition with Caraco Pharmaceutical Laboratories, USA
1996 Sales network expanded across 24 countries
1994 Launched initial public offer (IPO)
1989 Introduced gastroenterology products in India
1983 Established with a portfolio of five psychiatry products


Updated: May, 2019

India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically.